| Revue: | Anais brasileiros de dermatologia |
| Base de datos: | PERIÓDICA |
| Número de sistema: | 000404095 |
| ISSN: | 0365-0596 |
| Autores: | Carvalho, André Vicente Esteves de1 Romiti, Ricardo2 Souza, Cacilda da Silva2 Paschoal, Renato Soriani Milman, Laura de Mattos1 Meneghello, Luana Pizarro1 |
| Instituciones: | 1Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande do Sul. Brasil 2Universidade de Sao Paulo, Faculdade de Medicina, Sao Paulo. Brasil |
| Año: | 2016 |
| Periodo: | Nov-Dic |
| Volumen: | 91 |
| Número: | 6 |
| Paginación: | 781-790 |
| País: | Brasil |
| Idioma: | Inglés |
| Tipo de documento: | Artículo |
| Enfoque: | Analítico, descriptivo |
| Resumen en inglés | During the last decade, different studies have converged to evidence the high prevalence of comorbidities in subjects with psoriasis. Although a causal relation has not been fully elucidated, genetic relation, inflammatory pathways and/or common environmental factors appear to be underlying the development of psoriasis and the metabolic comorbidities. The concept of psoriasis as a systemic disease directed the attention of the scientific community in order to investigate the extent to which therapeutic interventions influence the onset and evolution of the most prevalent comorbidities in patients with psoriasis. This study presents scientific evidence of the influence of immunobiological treatments for psoriasis available in Brazil (infliximab, adalimumab, etanercept and ustekinumab) on the main comorbidities related to psoriasis. It highlights the importance of the inflammatory burden on the clinical outcome of patients, not only on disease activity, but also on the comorbidities. In this sense, systemic treatments, whether immunobiologicals or classic, can play a critical role to effectively control the inflammatory burden in psoriatic patients |
| Disciplinas: | Medicina |
| Palabras clave: | Dermatología, Terapéutica y rehabilitación, Psoriasis, Comorbilidad, Síndrome X metabólico, Factor de necrosis tumoral, Infliximab, Adalimumab, Etanercept, Ustekinumab |
| Keyword: | Medicine, Dermatology, Therapeutics and rehabilitation, Psoriasis, Comorbidity, Metabolic X syndrome, Tumor necrosis factor, Infliximab, Adalimumab, Etanercept, Ustekinumab |
| Texte intégral: | Texto completo (Ver HTML) |
